Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Aytu Biopharma (AYTU) over the last 7 years, with Q4 2025 value amounting to $29000.0.

  • Aytu Biopharma's Amortization of Deferred Charges rose 357.14% to $29000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $111000.0, marking a year-over-year decrease of 6828.57%. This contributed to the annual value of $108000.0 for FY2025, which is 8190.95% down from last year.
  • As of Q4 2025, Aytu Biopharma's Amortization of Deferred Charges stood at $29000.0, which was up 357.14% from $29000.0 recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Amortization of Deferred Charges ranged from a high of $170000.0 in Q4 2022 and a low of -$165000.0 during Q4 2021
  • For the 5-year period, Aytu Biopharma's Amortization of Deferred Charges averaged around $53100.0, with its median value being $63500.0 (2023).
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first plummeted by 45106.38% in 2021, then skyrocketed by 68823.53% in 2022.
  • Over the past 5 years, Aytu Biopharma's Amortization of Deferred Charges (Quarter) stood at -$165000.0 in 2021, then skyrocketed by 203.03% to $170000.0 in 2022, then decreased by 9.41% to $154000.0 in 2023, then plummeted by 81.82% to $28000.0 in 2024, then grew by 3.57% to $29000.0 in 2025.
  • Its Amortization of Deferred Charges was $29000.0 in Q4 2025, compared to $29000.0 in Q3 2025 and $26000.0 in Q2 2025.